Systemic Sclerosis-Associated Interstitial Lung Diseases

The FDA has granted fast-track designation for efzofitimod, a potential first-in-class immunomodulator, in the treatment of systemic sclerosis-associated interstitial lung disease, according to a press release from the drug’s manufacturer.

Higher blood neutrophil count and neutrophil-to-lymphocyte ratio predict more severe disease and increased mortality in patients with systemic sclerosis, according to data published in Arthritis Care and Research.